Iran threatens to go nuclear and produce weapon-grade uranium; warns US and Europe
uranium enrichment
to weapon-grade level. This threat implies that Tehran is moving forward with exiting the
Nuclear Non-Proliferation Treaty
(NPT) if Western countries move ahead and reimpose the United Nations sanctions, Iranian state media reported.
The latest uranium enrichment warning from Tehran came as Iranian lawmakers approved the general outlines of a bill aimed at expanding military readiness and increasing defense funding in response to threats from Israel, according to a Newsweek report.
Explore courses from Top Institutes in
Select a Course Category
Product Management
MBA
Project Management
Degree
CXO
Cybersecurity
Leadership
Data Science
others
Healthcare
MCA
Artificial Intelligence
Data Science
Public Policy
Data Analytics
Operations Management
Digital Marketing
Others
Management
healthcare
Finance
Technology
Design Thinking
PGDM
Skills you'll gain:
Creating Effective Product Roadmap
User Research & Translating it to Product Design
Key Metrics via Product Analytics
Hand-On Projects Using Cutting Edge Tools
Duration:
12 Weeks
Indian School of Business
ISB Product Management
Starts on
May 14, 2024
Get Details
Skills you'll gain:
Product Strategy & Roadmapping
User-Centric Product Design
Agile Product Development
Market Analysis & Product Launch
Duration:
24 Weeks
Indian School of Business
Professional Certificate in Product Management
Starts on
Jun 26, 2024
Get Details
Skills you'll gain:
Product Strategy & Competitive Advantage Tactics
Product Development Processes & Market Orientations
Product Analytics & Data-Driven Decision Making
Agile Development, Design Thinking, & Product Leadership
Duration:
40 Weeks
IIM Kozhikode
Professional Certificate in Product Management
Starts on
Jun 26, 2024
Get Details
The threat from Tehran is followed by rising pressure from the US and its European allies to bring back the
UN snapback sanctions
, which allow for the quick reimposition of previously lifted UN sanctions, mainly on Iran, if the country violates its nuclear deal commitments (the Joint Comprehensive Plan of Action (the JCPOA)).
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Start Your Intraday Trading Journey for Consistent Returns.
thefutureuniversity
Learn More
Undo
According to Axios, U.S. Secretary of State Marco Rubio and the foreign ministers of France, Germany, and the United Kingdom spoke over a phone call on Monday (July 14, 2025) and agreed to set an August deadline for a nuclear agreement.
If things don't fall in place and no deal is finalized by August 2025, the three European powers plan to enforce the UN "snapback" mechanism. If that happens, it will automatically reinstate global sanctions on Iran's arms trade, banking sector, and nuclear program.
Live Events
How have the US and France reacted
US President Donald Trump said, "They [Iran] would like to talk. I'm in no rush to talk because we obliterated their site," as quoted by Newsweek. French Foreign Minister Jean-Noel Barrot said, "Without a firm, tangible, and verifiable commitment from Iran, we will [trigger snapback] by the end of August at the latest."
Iranian Foreign Minister Abbas Araghchi warned, "This move would mark the end of Europe's role in Iran's peaceful nuclear file."
Why is this a reason to worry
If the UN snapback sanctions are brought back into play, it could be a step towards dismantling the 2015 Joint Comprehensive Plan of Action (JCPOA). It could prompt Tehran toward enriching uranium to weapons-grade levels of 90 percent.
The root of this crisis lies in the U.S. pulling out of the deal in 2018 under President Donald Trump, which prompted Iran to decrease its compliance and accelerate its nuclear activities.
The Israeli and U.S. strikes directly on Iran's nuclear facilities in June 2025, along with diplomatic actions in the Middle East, have further heightened tensions, and if Iran does exit the NPT, it could end international oversight of its nuclear activities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
5 minutes ago
- Economic Times
US second quarter GDP growth to reflect tariff turbulence
AP President Donald Trump attends a meeting with Israel's Prime Minister Benjamin Netanyahu in the Blue Room of the White House, Monday, July 7, 2025, in Washington. (AP Photo/Alex Brandon) US economic growth is expected to rebound in the second quarter, analysts said, in a momentary comeback reflecting trade shifts as companies tried to avoid the harshest of President Donald Trump's wide-ranging world's biggest economy is anticipated to expand at an annual rate of 2.5 percent in the April to June period, according to a consensus forecast by marks a reversal of a 0.5 percent decline, annualized, seen in the first three months of the cost pressures from tariffs, among other factors, could later bog down investment and consumption -- a key driver of the US economy. "It's very much distorted by the trade flows and inventory," said Nationwide chief economist Kathy Bostjancic, referring to second quarter growth. At the start of the year, businesses rushed to stock up on products in an effort to avoid Trump's threatened tariff hikes -- but this build-up is now imports surge ahead of tariff hikes in the first quarter led to the largest drag on GDP growth from net exports on record, analysts at Goldman Sachs said in a recent means a bounce back is expected once imports the acceleration is not sustainable, Bostjancic told had raised the idea of across-the-board tariffs targeting trading partners during election campaigning last year, and since returning to the US presidency in January he has rolled out wave after wave of fresh included a 10 percent levy on almost all US partners, higher duties on steel, aluminum and auto imports, as well as separate actions against Canada and Mexico over illegal immigration and illicit fentanyl April, the Trump administration separately took aim at the world's number two economy, China, as Beijing pushed back on US countries ended up imposing tit-for-tat tariffs on each other's products, reaching triple-digit levels and bringing many trade flows to a halt before Washington and Beijing reached a temporary agreement to lower two days of talks in the Swedish capital of Stockholm this week, negotiators from both countries signaled there could be an extension of the truce -- although the final call depends on Trump.- 'Clear deceleration' -Bostjancic expects that underlying activity driving US gross domestic product will be moderating, although not collapsing."The US economy continues to navigate a complex set of crosscurrents, obscuring a clear reading of its underlying momentum," said EY chief economist Gregory Daco in a he added that one trend is evident, which is that "economic activity is decelerating even as inflationary pressures are reemerging.""Tariff-induced cost pressures, persistent policy uncertainty, severely curtailed immigration, and elevated interest rates are collectively dampening employment, business investment and household consumption," Daco are closely eyeing the impact of Trump's tariffs on inflation, with economists warning that the duties could fuel price increases. They expect to learn more from data in the summer of this could impact consumer spending -- a key economic driver."The trend in GDP growth is best analyzed by considering the first and second quarters together," said Samuel Tombs, chief US economist at Pantheon Macroeconomics."The likely average growth rate of about 1.5 percent over these two quarters represents a clear deceleration from the 3 percent rates in the previous two years," he said in a note that the US economy would probably "lose more momentum" in the third quarter, when consumer prices for imported goods likely will rise "adverse consequences" of economic policy uncertainty will also start to materialize when it comes to business investment, Tombs have noted that companies tend to hold off major decisions during times of uncertainty, given the risk of sudden policy shifts."We continue to expect GDP growth to average just 1 percent in the second half of this year," Tombs said.
Economic Times
5 minutes ago
- Economic Times
Wegovy maker Novo's profit warning triggers $70 billion share rout
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market. ADVERTISEMENT Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started. Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously. Its shares plunged nearly 30% before paring some losses to trade down over 20% by mid-afternoon. The shares are now down 44% this year. "The magnitude of the guidance cut is a shocker," Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than "compounded" copycats to Wegovy. Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. U.S. law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations. ADVERTISEMENT The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the U.S., both for Wegovy and Ozempic in the GLP-1 diabetes market. The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen. ADVERTISEMENT At its peak in June 2024, Novo was worth as much as $615 billion, but its shares have plunged on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market. "The stock has gone from being a market darling to one of its biggest letdowns," said Angelo Meda, portfolio manager and head of equities at Banor SIM in Milan, which has a small Novo stake. "The biggest concern is the illegal channel siphoning away market share - something that's hard to quantify. Rebuilding trust will take time." ADVERTISEMENT Novo Nordisk share price in Danish krone Doustdar, an Iranian-born, Austrian national, who grew up in the United States, joined Novo in 1992 and will take on the new role on August 7. ADVERTISEMENT He currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. "We need to increase the sense of urgency and execute differently," Doustdar told investors and analysts on a call. "The fact that my announcement comes right after the guidance update, just makes the mandate ahead even more clear." Some analysts and investors had argued that Novo should select an American, or a person with extensive experience working in the United States as its next CEO. Novo has lost its first-mover advantage in the United States this year to U.S. rival Eli Lilly. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. In May, Novo said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22. "Unfortunately, our latest market research indicates that has not happened," Chief Financial Officer Karsten Munk Knudsen said on a call with analysts on Tuesday. One million or more U.S. patients are still using compounded GLP-1s, he said. Novo has stepped up its dialogue with the U.S. FDA to limit unlawful compounding of its drugs, the head of U.S. operations David Moore added on the call. "Compounding continues to be an issue that we have to address," Moore said. (You can now subscribe to our ETMarkets WhatsApp channel)
Economic Times
5 minutes ago
- Economic Times
Gold holds steady ahead of Fed policy statement
Gold prices steadied on Wednesday as investors held back on making big bets ahead of the Federal Reserve's policy statement later in the day for cues into future rate cuts, while focus remained on U.S. trade talks ahead of the August 1 deadline. ADVERTISEMENT * Spot gold was steady at $3,329.19 per ounce as of 0020 GMT. U.S. gold futures rose 0.1% to $3,327.70. * U.S. and Chinese officials agreed to seek an extension of their 90-day tariff truce on Tuesday, following two days of talks in Stockholm. * However, U.S. officials said it was up to President Donald Trump to decide whether to extend a trade truce that expires on August 12 or potentially let tariffs shoot back up to triple-digit figures. * Meanwhile, the U.S. dollar index held steady after hitting a more than one-month high on Tuesday, making greenback-priced bullion more expensive. ADVERTISEMENT * Investors turned their focus to the Fed's policy to gauge its future rate cut path, following the central bank's two-day meeting, during which it is widely expected to keep rates steady, despite Trump's constant call to lower them. * The U.S. trade deficit in goods narrowed to its lowest in nearly two years in June as imports fell sharply, cementing economists' expectations that trade likely accounted for much of an anticipated rebound in economic growth in the second quarter. ADVERTISEMENT * The International Monetary Fund slightly raised its global growth forecasts for 2025 and 2026 on Tuesday, citing stronger-than-expected buys ahead of a jump in U.S. tariffs on August 1 and a drop in the effective tariff rate to 17.3% from 24.4%. * Meanwhile, on Tuesday, Trump threatened tariffs and other measures on Russia "10 days from today" if Moscow showed no progress toward ending its more than three-year-long war in Ukraine. * Spot silver held steady at $38.20 per ounce, platinum fell 0.4% to $1,389.20 and palladium remain unchanged at $1,258.75. DATA/EVENTS (GMT) 0530 France GDP preliminary QQ Q2 0800 Germany GDP flash QQ SA, YY NSA Q2 0900 EU GDP flash preliminary QQ, YY Q2 0900 EU consumer confidence final July 1230 U.S. GDP advance Q2. (You can now subscribe to our ETMarkets WhatsApp channel)
